Masimo (MASI) Aandelenoverzicht
Masimo Corporation houdt zich bezig met de ontwikkeling, productie en marketing van verschillende patiëntbewakingstechnologieën en automatiserings- en connectiviteitsoplossingen wereldwijd. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
MASI Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Masimo Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$178.79 |
| 52 Week Hoogtepunt | US$179.00 |
| 52 Week Laag | US$125.94 |
| Bèta | 1.13 |
| 1 maand verandering | 0.19% |
| 3 maanden verandering | 1.97% |
| 1 Jaar Verandering | 19.68% |
| 3 jaar verandering | 12.79% |
| 5 jaar verandering | -17.15% |
| Verandering sinds IPO | 755.45% |
Recent nieuws en updates
MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate
The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path
The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.Recent updates
MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate
The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path
The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.MASI: Danaher Cash Offer And Patent Rulings Will Shape Deal Outcome
Analysts kept Masimo's fair value estimate steady at $178.60 while aligning their price targets around the agreed $180 per share cash acquisition by Danaher, with recent rating changes reflecting the view that any potential upside is now largely tied to the deal closing as planned. Analyst Commentary Recent research on Masimo centers on the agreed US$180 per share cash offer from Danaher, with ratings and targets now clustered around that level.MASI: Danaher Cash Deal And Legal Overhang Will Frame Future Returns
The updated analyst price target for Masimo edges down by $0.15 to $178.60, as analysts anchor their views to Danaher's agreed $180 per share cash acquisition and recent rating moves to Neutral or No Rating. Analyst Commentary Recent research around Masimo has centered on the agreed US$180 per share cash acquisition by Danaher, with most analysts reframing their views around deal completion rather than standalone upside or downside.MASI: Danaher Cash Buyout Will Define Future Returns And Key Risks
Analysts have trimmed their Masimo fair value estimate from $183.13 to $178.75 to align expectations with the agreed $180 per share cash acquisition by Danaher. This shift is reflected in new Hold and Neutral ratings that are centered around the $180 level.Masimo: Danaher Acquisition Saves The Company From Lackluster Performance
Summary Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. The acquisition offers a strong strategic fit, combining MASI's non-invasive oximetry with DHR's invasive diagnostics for comprehensive acute care solutions. Shareholders benefit from a 34% stock price surge and a potential 2.8% spread to deal close, with minimal market risk. Holding MASI shares until the deal closes offers a relatively safe, low-stress return, though opportunity cost and regulatory risk remain. Read the full article on Seeking AlphaMASI: Renewed Philips Partnership Will Drive Outperformance Despite Market Challenges
Analysts have adjusted their price target for Masimo downward from approximately $188 to $183. This change is attributed to shifts in revenue growth estimates and a strengthening profit margin following recent partnership developments and ongoing market challenges.Is Masimo Corporation (NASDAQ:MASI) Potentially Undervalued?
Masimo Corporation ( NASDAQ:MASI ), might not be a large cap stock, but it received a lot of attention from a...Calculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Masimo fair value estimate is US$136 Masimo's US$154 share...Is Masimo (NASDAQ:MASI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?
Masimo Corporation ( NASDAQ:MASI ), is not the largest company out there, but it saw significant share price movement...Masimo: Priced Dearly Given Uncertainty
Summary Masimo Corporation, a mid-cap healthcare firm, has a new CEO and is navigating considerable uncertainty. Some aspects of the company's divestiture of its consumer business are still unclear. Despite this, the stock is generally well liked within the analyst firm community, following solid Q4 results. An analysis around Masimo Corporation follows in the paragraphs below. Read the full article on Seeking AlphaMasimo: A Stellar Performance After The Dust Has Settled
Summary Masimo's proxy fight and Sound United acquisition distracted from the core business, but resolution and focus on healthcare are driving value and momentum. Shares surged over 50% since July due to strong Q2 results and improved earnings guidance, despite ongoing challenges and leadership changes. Current valuations are demanding, suggesting an opportune time for profit taking, while I maintain a position for long-term growth potential. Divesting Sound United could reduce debt, enhancing focus on the core med-tech business with promising double-digit organic growth. Read the full article on Seeking AlphaMasimo Corporation: Too Much Uncertainty For Now
Summary Masimo Corporation's stock has underperformed, with shares down 6% versus SPY's 15% increase, due to mixed margins and lack of meaningful catalysts. The company's financials show low ROA, ROE, and ROTC, with tight margins and a concerning interest coverage ratio of 2.6x. The sale of Sound United and recent partnerships with Google and Qualcomm offer potential, but the future growth sustainability remains uncertain. Internal management struggles and recent board shakeup add to the volatility, making me cautious and opting to stay on the sidelines for now. Read the full article on Seeking Alpha
Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph
Increased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.Rendement voor aandeelhouders
| MASI | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 0.2% | 4.0% | -0.3% |
| 1Y | 19.7% | -18.6% | 26.7% |
Rendement versus industrie: MASI overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement -18.6 % opleverde.
Rendement versus markt: MASI presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 26.7 % opleverde.
Prijsvolatiliteit
| MASI volatility | |
|---|---|
| MASI Average Weekly Movement | 0.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: MASI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van MASI is het afgelopen jaar gedaald van 6% naar 1%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1989 | 2,200 | Katie Szyman | www.masimo.com |
Masimo Corporation houdt zich bezig met de ontwikkeling, productie en marketing van verschillende patiëntbewakingstechnologieën en automatiserings- en connectiviteitsoplossingen wereldwijd. Het bedrijf biedt Masimo Signal Extraction Technology (SET) pulsoximetrie met doorlopende beweging en pulsoximetriebewaking met lage perfusie om de belangrijkste beperkingen van conventionele pulsoximetrie aan te pakken; Masimo Rainbow SET-platform, inclusief SET Pulse CO-Oximetry-producten van de regenboog die niet-invasieve bewaking van zuurstof, carboxyhemoglobine en methemoglobine mogelijk maakt. Het biedt ook oplossingen voor hersenfunctie- en hemodynamische bewaking; het volgen van de positie en activiteit van de patiënt, en neuromodulatietechnologie-oplossingen; en het Masimo Hospital Automation-platform, inclusief oplossingen voor ziekenhuisautomatisering, waaronder Patient SafetyNet, Iris, iSirona, Replica en UniView; en oplossingen voor hersenfunctiebewaking, hemodynamische bewaking, regionale oximetrie, akoestische ademhalingsfrequentiebewaking, capnografie en gasbewaking, en telehealth-oplossingen.
Masimo Corporation Samenvatting
| MASI fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$9.36b |
| Inkomsten(TTM) | US$216.80m |
| Inkomsten(TTM) | US$1.56b |
Is MASI overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MASI resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.56b |
| Kosten van inkomsten | US$598.00m |
| Brutowinst | US$960.50m |
| Overige uitgaven | US$743.70m |
| Inkomsten | US$216.80m |
Laatst gerapporteerde inkomsten
Apr 04, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 4.14 |
| Brutomarge | 61.63% |
| Nettowinstmarge | 13.91% |
| Schuld/Eigen Vermogen Verhouding | 57.3% |
Hoe presteerde MASI op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/20 12:46 |
| Aandelenkoers aan het einde van de dag | 2026/05/20 00:00 |
| Inkomsten | 2026/04/04 |
| Jaarlijkse inkomsten | 2026/01/03 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Masimo Corporation wordt gevolgd door 22 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Michael Polark | Baird |
| Charley Jones | Barrington Research Associates, Inc. |
| Ravi Misra | Berenberg |